NEUROPSYCHOPHARMACOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2143658, encodeId=dce921436588c, content=已投稿的状态持续了半个月了，没有消息，各位同仁给建议一下这是婉拒吗。接着等有必要吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6af58641061, createdName=ms4000001321959273, createdTime=Mon Jun 19 14:16:23 CST 2023, time=2023-06-19, status=1, ipAttribution=宁夏), GetPortalCommentsPageByObjectIdResponse(id=475610, encodeId=ecde4e56106e, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：在上面中了三篇，比较容易，投着玩一玩可以来这。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=746, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=浙江大学医学院, createdTime=Sat Jun 11 18:30:00 CST 2011, time=2011-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=473238, encodeId=7e8f4e32385e, content=under review12天，被拒。 杂志审稿人都是很牛的专家，提出的问题棘手又相当专业。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=659, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=nananoko, createdTime=Thu Jan 06 15:41:00 CST 2011, time=2011-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560799, encodeId=b496560e998e, content=大神可以提供一下PMID么？想学习下ngx7912156 2017-10-25 发表:: 研究方向：中医药;神经再生;神经系统疾病接收率：约50% 审稿时间：约2个月 SCI(2016)：6.403 SCI(2015)：6.399 复方中药制剂ngx7912156 2017-10-25 14:48:00 发表: 复方中药制剂, beContent=ngx7912156 2017-10-25 发表:: 研究方向：中医药;神经再生;神经系统疾病接收率：约50% 审稿时间：约2个月 SCI(2016)：6.403 SCI(2015)：6.399 复方中药制剂, objectType=tool_impact_factor, channel=null, level=null, likeNumber=328, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/16/5216d8362228f28bb1314281182c775b.jpg, createdBy=b64f1989189, createdName=京墨, createdTime=Thu Sep 06 00:00:00 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090445, encodeId=b88120904454a, content=请问accept多久后会受到proof邮件？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fa2c2358137, createdName=122c6795m57(暂无昵称), createdTime=Mon Sep 26 14:49:46 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229469, encodeId=40a61229469da, content=想问问这个杂志会要western blot的全膜吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a5e8120865, createdName=ms5000001165594838, createdTime=Wed Jun 29 14:54:14 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096008, encodeId=346c109600846, content=讨论一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096007, encodeId=cde3109600e27, content=引言和讨论之间有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548573, encodeId=275f5485e33e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：复方中药制剂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=373, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7581398151, createdName=ngx7912156, createdTime=Wed Oct 25 14:48:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547815, encodeId=241754e8152c, content=不知道怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=423, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/YConHRH5GCtcFEWO7xCkB10VsePH8PlzvattQoVRIQ7KJg26g6PvbkD8nE6Gsic5Nub2HzA4TsvkTQqEYUoz7pw/132, createdBy=288f2160779, createdName=liyu5975, createdTime=Sat Sep 30 14:40:00 CST 2017, time=2017-09-30, status=1, ipAttribution=)]

2023-06-19 ms4000001321959273 来自宁夏

已投稿的状态持续了半个月了，没有消息，各位同仁给建议一下这是婉拒吗。接着等有必要吗

40 0

[GetPortalCommentsPageByObjectIdResponse(id=2143658, encodeId=dce921436588c, content=已投稿的状态持续了半个月了，没有消息，各位同仁给建议一下这是婉拒吗。接着等有必要吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6af58641061, createdName=ms4000001321959273, createdTime=Mon Jun 19 14:16:23 CST 2023, time=2023-06-19, status=1, ipAttribution=宁夏), GetPortalCommentsPageByObjectIdResponse(id=475610, encodeId=ecde4e56106e, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：在上面中了三篇，比较容易，投着玩一玩可以来这。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=746, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=浙江大学医学院, createdTime=Sat Jun 11 18:30:00 CST 2011, time=2011-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=473238, encodeId=7e8f4e32385e, content=under review12天，被拒。 杂志审稿人都是很牛的专家，提出的问题棘手又相当专业。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=659, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=nananoko, createdTime=Thu Jan 06 15:41:00 CST 2011, time=2011-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560799, encodeId=b496560e998e, content=大神可以提供一下PMID么？想学习下ngx7912156 2017-10-25 发表:: 研究方向：中医药;神经再生;神经系统疾病接收率：约50% 审稿时间：约2个月 SCI(2016)：6.403 SCI(2015)：6.399 复方中药制剂ngx7912156 2017-10-25 14:48:00 发表: 复方中药制剂, beContent=ngx7912156 2017-10-25 发表:: 研究方向：中医药;神经再生;神经系统疾病接收率：约50% 审稿时间：约2个月 SCI(2016)：6.403 SCI(2015)：6.399 复方中药制剂, objectType=tool_impact_factor, channel=null, level=null, likeNumber=328, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/16/5216d8362228f28bb1314281182c775b.jpg, createdBy=b64f1989189, createdName=京墨, createdTime=Thu Sep 06 00:00:00 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090445, encodeId=b88120904454a, content=请问accept多久后会受到proof邮件？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fa2c2358137, createdName=122c6795m57(暂无昵称), createdTime=Mon Sep 26 14:49:46 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229469, encodeId=40a61229469da, content=想问问这个杂志会要western blot的全膜吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a5e8120865, createdName=ms5000001165594838, createdTime=Wed Jun 29 14:54:14 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096008, encodeId=346c109600846, content=讨论一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096007, encodeId=cde3109600e27, content=引言和讨论之间有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548573, encodeId=275f5485e33e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：复方中药制剂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=373, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7581398151, createdName=ngx7912156, createdTime=Wed Oct 25 14:48:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547815, encodeId=241754e8152c, content=不知道怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=423, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/YConHRH5GCtcFEWO7xCkB10VsePH8PlzvattQoVRIQ7KJg26g6PvbkD8nE6Gsic5Nub2HzA4TsvkTQqEYUoz7pw/132, createdBy=288f2160779, createdName=liyu5975, createdTime=Sat Sep 30 14:40:00 CST 2017, time=2017-09-30, status=1, ipAttribution=)]

2011-06-11 浙江大学医学院

审稿速度:2.0 | 投稿命中率:75.0
经验分享：在上面中了三篇，比较容易，投着玩一玩可以来这。

746 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2143658, encodeId=dce921436588c, content=已投稿的状态持续了半个月了，没有消息，各位同仁给建议一下这是婉拒吗。接着等有必要吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6af58641061, createdName=ms4000001321959273, createdTime=Mon Jun 19 14:16:23 CST 2023, time=2023-06-19, status=1, ipAttribution=宁夏), GetPortalCommentsPageByObjectIdResponse(id=475610, encodeId=ecde4e56106e, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：在上面中了三篇，比较容易，投着玩一玩可以来这。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=746, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=浙江大学医学院, createdTime=Sat Jun 11 18:30:00 CST 2011, time=2011-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=473238, encodeId=7e8f4e32385e, content=under review12天，被拒。 杂志审稿人都是很牛的专家，提出的问题棘手又相当专业。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=659, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=nananoko, createdTime=Thu Jan 06 15:41:00 CST 2011, time=2011-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560799, encodeId=b496560e998e, content=大神可以提供一下PMID么？想学习下ngx7912156 2017-10-25 发表:: 研究方向：中医药;神经再生;神经系统疾病接收率：约50% 审稿时间：约2个月 SCI(2016)：6.403 SCI(2015)：6.399 复方中药制剂ngx7912156 2017-10-25 14:48:00 发表: 复方中药制剂, beContent=ngx7912156 2017-10-25 发表:: 研究方向：中医药;神经再生;神经系统疾病接收率：约50% 审稿时间：约2个月 SCI(2016)：6.403 SCI(2015)：6.399 复方中药制剂, objectType=tool_impact_factor, channel=null, level=null, likeNumber=328, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/16/5216d8362228f28bb1314281182c775b.jpg, createdBy=b64f1989189, createdName=京墨, createdTime=Thu Sep 06 00:00:00 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090445, encodeId=b88120904454a, content=请问accept多久后会受到proof邮件？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fa2c2358137, createdName=122c6795m57(暂无昵称), createdTime=Mon Sep 26 14:49:46 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229469, encodeId=40a61229469da, content=想问问这个杂志会要western blot的全膜吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a5e8120865, createdName=ms5000001165594838, createdTime=Wed Jun 29 14:54:14 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096008, encodeId=346c109600846, content=讨论一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096007, encodeId=cde3109600e27, content=引言和讨论之间有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548573, encodeId=275f5485e33e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：复方中药制剂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=373, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7581398151, createdName=ngx7912156, createdTime=Wed Oct 25 14:48:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547815, encodeId=241754e8152c, content=不知道怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=423, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/YConHRH5GCtcFEWO7xCkB10VsePH8PlzvattQoVRIQ7KJg26g6PvbkD8nE6Gsic5Nub2HzA4TsvkTQqEYUoz7pw/132, createdBy=288f2160779, createdName=liyu5975, createdTime=Sat Sep 30 14:40:00 CST 2017, time=2017-09-30, status=1, ipAttribution=)]

2011-01-06 nananoko

under review12天，被拒。
杂志审稿人都是很牛的专家，提出的问题棘手又相当专业。

659 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2143658, encodeId=dce921436588c, content=已投稿的状态持续了半个月了，没有消息，各位同仁给建议一下这是婉拒吗。接着等有必要吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6af58641061, createdName=ms4000001321959273, createdTime=Mon Jun 19 14:16:23 CST 2023, time=2023-06-19, status=1, ipAttribution=宁夏), GetPortalCommentsPageByObjectIdResponse(id=475610, encodeId=ecde4e56106e, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：在上面中了三篇，比较容易，投着玩一玩可以来这。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=746, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=浙江大学医学院, createdTime=Sat Jun 11 18:30:00 CST 2011, time=2011-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=473238, encodeId=7e8f4e32385e, content=under review12天，被拒。 杂志审稿人都是很牛的专家，提出的问题棘手又相当专业。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=659, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=nananoko, createdTime=Thu Jan 06 15:41:00 CST 2011, time=2011-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560799, encodeId=b496560e998e, content=大神可以提供一下PMID么？想学习下ngx7912156 2017-10-25 发表:: 研究方向：中医药;神经再生;神经系统疾病接收率：约50% 审稿时间：约2个月 SCI(2016)：6.403 SCI(2015)：6.399 复方中药制剂ngx7912156 2017-10-25 14:48:00 发表: 复方中药制剂, beContent=ngx7912156 2017-10-25 发表:: 研究方向：中医药;神经再生;神经系统疾病接收率：约50% 审稿时间：约2个月 SCI(2016)：6.403 SCI(2015)：6.399 复方中药制剂, objectType=tool_impact_factor, channel=null, level=null, likeNumber=328, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/16/5216d8362228f28bb1314281182c775b.jpg, createdBy=b64f1989189, createdName=京墨, createdTime=Thu Sep 06 00:00:00 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090445, encodeId=b88120904454a, content=请问accept多久后会受到proof邮件？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fa2c2358137, createdName=122c6795m57(暂无昵称), createdTime=Mon Sep 26 14:49:46 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229469, encodeId=40a61229469da, content=想问问这个杂志会要western blot的全膜吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a5e8120865, createdName=ms5000001165594838, createdTime=Wed Jun 29 14:54:14 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096008, encodeId=346c109600846, content=讨论一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096007, encodeId=cde3109600e27, content=引言和讨论之间有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548573, encodeId=275f5485e33e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：复方中药制剂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=373, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7581398151, createdName=ngx7912156, createdTime=Wed Oct 25 14:48:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547815, encodeId=241754e8152c, content=不知道怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=423, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/YConHRH5GCtcFEWO7xCkB10VsePH8PlzvattQoVRIQ7KJg26g6PvbkD8nE6Gsic5Nub2HzA4TsvkTQqEYUoz7pw/132, createdBy=288f2160779, createdName=liyu5975, createdTime=Sat Sep 30 14:40:00 CST 2017, time=2017-09-30, status=1, ipAttribution=)]

2018-09-06 京墨

大神可以提供一下PMID么？想学习下ngx7912156 2017-10-25 发表::
研究方向：中医药;神经再生;神经系统疾病接收率：约50% 审稿时间：约2个月 SCI(2016)：6.403 SCI(2015)：6.399 复方中药制剂ngx7912156 2017-10-25 14:48:00 发表:
复方中药制剂

ngx7912156 2017-10-25 发表:: 研究方向：中医药;神经再生;神经系统疾病接收率：约50% 审稿时间：约2个月 SCI(2016)：6.403 SCI(2015)：6.399 复方中药制剂

328 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2143658, encodeId=dce921436588c, content=已投稿的状态持续了半个月了，没有消息，各位同仁给建议一下这是婉拒吗。接着等有必要吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6af58641061, createdName=ms4000001321959273, createdTime=Mon Jun 19 14:16:23 CST 2023, time=2023-06-19, status=1, ipAttribution=宁夏), GetPortalCommentsPageByObjectIdResponse(id=475610, encodeId=ecde4e56106e, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：在上面中了三篇，比较容易，投着玩一玩可以来这。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=746, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=浙江大学医学院, createdTime=Sat Jun 11 18:30:00 CST 2011, time=2011-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=473238, encodeId=7e8f4e32385e, content=under review12天，被拒。 杂志审稿人都是很牛的专家，提出的问题棘手又相当专业。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=659, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=nananoko, createdTime=Thu Jan 06 15:41:00 CST 2011, time=2011-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560799, encodeId=b496560e998e, content=大神可以提供一下PMID么？想学习下ngx7912156 2017-10-25 发表:: 研究方向：中医药;神经再生;神经系统疾病接收率：约50% 审稿时间：约2个月 SCI(2016)：6.403 SCI(2015)：6.399 复方中药制剂ngx7912156 2017-10-25 14:48:00 发表: 复方中药制剂, beContent=ngx7912156 2017-10-25 发表:: 研究方向：中医药;神经再生;神经系统疾病接收率：约50% 审稿时间：约2个月 SCI(2016)：6.403 SCI(2015)：6.399 复方中药制剂, objectType=tool_impact_factor, channel=null, level=null, likeNumber=328, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/16/5216d8362228f28bb1314281182c775b.jpg, createdBy=b64f1989189, createdName=京墨, createdTime=Thu Sep 06 00:00:00 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090445, encodeId=b88120904454a, content=请问accept多久后会受到proof邮件？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fa2c2358137, createdName=122c6795m57(暂无昵称), createdTime=Mon Sep 26 14:49:46 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229469, encodeId=40a61229469da, content=想问问这个杂志会要western blot的全膜吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a5e8120865, createdName=ms5000001165594838, createdTime=Wed Jun 29 14:54:14 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096008, encodeId=346c109600846, content=讨论一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096007, encodeId=cde3109600e27, content=引言和讨论之间有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548573, encodeId=275f5485e33e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：复方中药制剂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=373, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7581398151, createdName=ngx7912156, createdTime=Wed Oct 25 14:48:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547815, encodeId=241754e8152c, content=不知道怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=423, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/YConHRH5GCtcFEWO7xCkB10VsePH8PlzvattQoVRIQ7KJg26g6PvbkD8nE6Gsic5Nub2HzA4TsvkTQqEYUoz7pw/132, createdBy=288f2160779, createdName=liyu5975, createdTime=Sat Sep 30 14:40:00 CST 2017, time=2017-09-30, status=1, ipAttribution=)]

2022-09-26 122c6795m57(暂无昵称)

请问accept多久后会受到proof邮件？

47 0

[GetPortalCommentsPageByObjectIdResponse(id=2143658, encodeId=dce921436588c, content=已投稿的状态持续了半个月了，没有消息，各位同仁给建议一下这是婉拒吗。接着等有必要吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6af58641061, createdName=ms4000001321959273, createdTime=Mon Jun 19 14:16:23 CST 2023, time=2023-06-19, status=1, ipAttribution=宁夏), GetPortalCommentsPageByObjectIdResponse(id=475610, encodeId=ecde4e56106e, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：在上面中了三篇，比较容易，投着玩一玩可以来这。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=746, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=浙江大学医学院, createdTime=Sat Jun 11 18:30:00 CST 2011, time=2011-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=473238, encodeId=7e8f4e32385e, content=under review12天，被拒。 杂志审稿人都是很牛的专家，提出的问题棘手又相当专业。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=659, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=nananoko, createdTime=Thu Jan 06 15:41:00 CST 2011, time=2011-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560799, encodeId=b496560e998e, content=大神可以提供一下PMID么？想学习下ngx7912156 2017-10-25 发表:: 研究方向：中医药;神经再生;神经系统疾病接收率：约50% 审稿时间：约2个月 SCI(2016)：6.403 SCI(2015)：6.399 复方中药制剂ngx7912156 2017-10-25 14:48:00 发表: 复方中药制剂, beContent=ngx7912156 2017-10-25 发表:: 研究方向：中医药;神经再生;神经系统疾病接收率：约50% 审稿时间：约2个月 SCI(2016)：6.403 SCI(2015)：6.399 复方中药制剂, objectType=tool_impact_factor, channel=null, level=null, likeNumber=328, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/16/5216d8362228f28bb1314281182c775b.jpg, createdBy=b64f1989189, createdName=京墨, createdTime=Thu Sep 06 00:00:00 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090445, encodeId=b88120904454a, content=请问accept多久后会受到proof邮件？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fa2c2358137, createdName=122c6795m57(暂无昵称), createdTime=Mon Sep 26 14:49:46 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229469, encodeId=40a61229469da, content=想问问这个杂志会要western blot的全膜吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a5e8120865, createdName=ms5000001165594838, createdTime=Wed Jun 29 14:54:14 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096008, encodeId=346c109600846, content=讨论一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096007, encodeId=cde3109600e27, content=引言和讨论之间有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548573, encodeId=275f5485e33e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：复方中药制剂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=373, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7581398151, createdName=ngx7912156, createdTime=Wed Oct 25 14:48:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547815, encodeId=241754e8152c, content=不知道怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=423, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/YConHRH5GCtcFEWO7xCkB10VsePH8PlzvattQoVRIQ7KJg26g6PvbkD8nE6Gsic5Nub2HzA4TsvkTQqEYUoz7pw/132, createdBy=288f2160779, createdName=liyu5975, createdTime=Sat Sep 30 14:40:00 CST 2017, time=2017-09-30, status=1, ipAttribution=)]

2022-06-29 ms5000001165594838

想问问这个杂志会要western blot的全膜吗

54 0

[GetPortalCommentsPageByObjectIdResponse(id=2143658, encodeId=dce921436588c, content=已投稿的状态持续了半个月了，没有消息，各位同仁给建议一下这是婉拒吗。接着等有必要吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6af58641061, createdName=ms4000001321959273, createdTime=Mon Jun 19 14:16:23 CST 2023, time=2023-06-19, status=1, ipAttribution=宁夏), GetPortalCommentsPageByObjectIdResponse(id=475610, encodeId=ecde4e56106e, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：在上面中了三篇，比较容易，投着玩一玩可以来这。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=746, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=浙江大学医学院, createdTime=Sat Jun 11 18:30:00 CST 2011, time=2011-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=473238, encodeId=7e8f4e32385e, content=under review12天，被拒。 杂志审稿人都是很牛的专家，提出的问题棘手又相当专业。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=659, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=nananoko, createdTime=Thu Jan 06 15:41:00 CST 2011, time=2011-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560799, encodeId=b496560e998e, content=大神可以提供一下PMID么？想学习下ngx7912156 2017-10-25 发表:: 研究方向：中医药;神经再生;神经系统疾病接收率：约50% 审稿时间：约2个月 SCI(2016)：6.403 SCI(2015)：6.399 复方中药制剂ngx7912156 2017-10-25 14:48:00 发表: 复方中药制剂, beContent=ngx7912156 2017-10-25 发表:: 研究方向：中医药;神经再生;神经系统疾病接收率：约50% 审稿时间：约2个月 SCI(2016)：6.403 SCI(2015)：6.399 复方中药制剂, objectType=tool_impact_factor, channel=null, level=null, likeNumber=328, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/16/5216d8362228f28bb1314281182c775b.jpg, createdBy=b64f1989189, createdName=京墨, createdTime=Thu Sep 06 00:00:00 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090445, encodeId=b88120904454a, content=请问accept多久后会受到proof邮件？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fa2c2358137, createdName=122c6795m57(暂无昵称), createdTime=Mon Sep 26 14:49:46 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229469, encodeId=40a61229469da, content=想问问这个杂志会要western blot的全膜吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a5e8120865, createdName=ms5000001165594838, createdTime=Wed Jun 29 14:54:14 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096008, encodeId=346c109600846, content=讨论一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096007, encodeId=cde3109600e27, content=引言和讨论之间有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548573, encodeId=275f5485e33e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：复方中药制剂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=373, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7581398151, createdName=ngx7912156, createdTime=Wed Oct 25 14:48:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547815, encodeId=241754e8152c, content=不知道怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=423, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/YConHRH5GCtcFEWO7xCkB10VsePH8PlzvattQoVRIQ7KJg26g6PvbkD8nE6Gsic5Nub2HzA4TsvkTQqEYUoz7pw/132, createdBy=288f2160779, createdName=liyu5975, createdTime=Sat Sep 30 14:40:00 CST 2017, time=2017-09-30, status=1, ipAttribution=)]

2021-12-29 MS68862005

讨论一般分几段？

66 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2143658, encodeId=dce921436588c, content=已投稿的状态持续了半个月了，没有消息，各位同仁给建议一下这是婉拒吗。接着等有必要吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6af58641061, createdName=ms4000001321959273, createdTime=Mon Jun 19 14:16:23 CST 2023, time=2023-06-19, status=1, ipAttribution=宁夏), GetPortalCommentsPageByObjectIdResponse(id=475610, encodeId=ecde4e56106e, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：在上面中了三篇，比较容易，投着玩一玩可以来这。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=746, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=浙江大学医学院, createdTime=Sat Jun 11 18:30:00 CST 2011, time=2011-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=473238, encodeId=7e8f4e32385e, content=under review12天，被拒。 杂志审稿人都是很牛的专家，提出的问题棘手又相当专业。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=659, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=nananoko, createdTime=Thu Jan 06 15:41:00 CST 2011, time=2011-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560799, encodeId=b496560e998e, content=大神可以提供一下PMID么？想学习下ngx7912156 2017-10-25 发表:: 研究方向：中医药;神经再生;神经系统疾病接收率：约50% 审稿时间：约2个月 SCI(2016)：6.403 SCI(2015)：6.399 复方中药制剂ngx7912156 2017-10-25 14:48:00 发表: 复方中药制剂, beContent=ngx7912156 2017-10-25 发表:: 研究方向：中医药;神经再生;神经系统疾病接收率：约50% 审稿时间：约2个月 SCI(2016)：6.403 SCI(2015)：6.399 复方中药制剂, objectType=tool_impact_factor, channel=null, level=null, likeNumber=328, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/16/5216d8362228f28bb1314281182c775b.jpg, createdBy=b64f1989189, createdName=京墨, createdTime=Thu Sep 06 00:00:00 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090445, encodeId=b88120904454a, content=请问accept多久后会受到proof邮件？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fa2c2358137, createdName=122c6795m57(暂无昵称), createdTime=Mon Sep 26 14:49:46 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229469, encodeId=40a61229469da, content=想问问这个杂志会要western blot的全膜吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a5e8120865, createdName=ms5000001165594838, createdTime=Wed Jun 29 14:54:14 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096008, encodeId=346c109600846, content=讨论一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096007, encodeId=cde3109600e27, content=引言和讨论之间有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548573, encodeId=275f5485e33e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：复方中药制剂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=373, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7581398151, createdName=ngx7912156, createdTime=Wed Oct 25 14:48:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547815, encodeId=241754e8152c, content=不知道怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=423, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/YConHRH5GCtcFEWO7xCkB10VsePH8PlzvattQoVRIQ7KJg26g6PvbkD8nE6Gsic5Nub2HzA4TsvkTQqEYUoz7pw/132, createdBy=288f2160779, createdName=liyu5975, createdTime=Sat Sep 30 14:40:00 CST 2017, time=2017-09-30, status=1, ipAttribution=)]

2021-12-28 Mia

引言和讨论之间有什么区别？

65 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2143658, encodeId=dce921436588c, content=已投稿的状态持续了半个月了，没有消息，各位同仁给建议一下这是婉拒吗。接着等有必要吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6af58641061, createdName=ms4000001321959273, createdTime=Mon Jun 19 14:16:23 CST 2023, time=2023-06-19, status=1, ipAttribution=宁夏), GetPortalCommentsPageByObjectIdResponse(id=475610, encodeId=ecde4e56106e, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：在上面中了三篇，比较容易，投着玩一玩可以来这。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=746, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=浙江大学医学院, createdTime=Sat Jun 11 18:30:00 CST 2011, time=2011-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=473238, encodeId=7e8f4e32385e, content=under review12天，被拒。 杂志审稿人都是很牛的专家，提出的问题棘手又相当专业。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=659, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=nananoko, createdTime=Thu Jan 06 15:41:00 CST 2011, time=2011-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560799, encodeId=b496560e998e, content=大神可以提供一下PMID么？想学习下ngx7912156 2017-10-25 发表:: 研究方向：中医药;神经再生;神经系统疾病接收率：约50% 审稿时间：约2个月 SCI(2016)：6.403 SCI(2015)：6.399 复方中药制剂ngx7912156 2017-10-25 14:48:00 发表: 复方中药制剂, beContent=ngx7912156 2017-10-25 发表:: 研究方向：中医药;神经再生;神经系统疾病接收率：约50% 审稿时间：约2个月 SCI(2016)：6.403 SCI(2015)：6.399 复方中药制剂, objectType=tool_impact_factor, channel=null, level=null, likeNumber=328, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/16/5216d8362228f28bb1314281182c775b.jpg, createdBy=b64f1989189, createdName=京墨, createdTime=Thu Sep 06 00:00:00 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090445, encodeId=b88120904454a, content=请问accept多久后会受到proof邮件？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fa2c2358137, createdName=122c6795m57(暂无昵称), createdTime=Mon Sep 26 14:49:46 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229469, encodeId=40a61229469da, content=想问问这个杂志会要western blot的全膜吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a5e8120865, createdName=ms5000001165594838, createdTime=Wed Jun 29 14:54:14 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096008, encodeId=346c109600846, content=讨论一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096007, encodeId=cde3109600e27, content=引言和讨论之间有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548573, encodeId=275f5485e33e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：复方中药制剂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=373, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7581398151, createdName=ngx7912156, createdTime=Wed Oct 25 14:48:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547815, encodeId=241754e8152c, content=不知道怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=423, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/YConHRH5GCtcFEWO7xCkB10VsePH8PlzvattQoVRIQ7KJg26g6PvbkD8nE6Gsic5Nub2HzA4TsvkTQqEYUoz7pw/132, createdBy=288f2160779, createdName=liyu5975, createdTime=Sat Sep 30 14:40:00 CST 2017, time=2017-09-30, status=1, ipAttribution=)]

2017-10-25 ngx7912156

审稿速度:2.0 | 投稿命中率:50.0
经验分享：复方中药制剂

373 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2143658, encodeId=dce921436588c, content=已投稿的状态持续了半个月了，没有消息，各位同仁给建议一下这是婉拒吗。接着等有必要吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6af58641061, createdName=ms4000001321959273, createdTime=Mon Jun 19 14:16:23 CST 2023, time=2023-06-19, status=1, ipAttribution=宁夏), GetPortalCommentsPageByObjectIdResponse(id=475610, encodeId=ecde4e56106e, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：在上面中了三篇，比较容易，投着玩一玩可以来这。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=746, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=浙江大学医学院, createdTime=Sat Jun 11 18:30:00 CST 2011, time=2011-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=473238, encodeId=7e8f4e32385e, content=under review12天，被拒。 杂志审稿人都是很牛的专家，提出的问题棘手又相当专业。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=659, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=nananoko, createdTime=Thu Jan 06 15:41:00 CST 2011, time=2011-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560799, encodeId=b496560e998e, content=大神可以提供一下PMID么？想学习下ngx7912156 2017-10-25 发表:: 研究方向：中医药;神经再生;神经系统疾病接收率：约50% 审稿时间：约2个月 SCI(2016)：6.403 SCI(2015)：6.399 复方中药制剂ngx7912156 2017-10-25 14:48:00 发表: 复方中药制剂, beContent=ngx7912156 2017-10-25 发表:: 研究方向：中医药;神经再生;神经系统疾病接收率：约50% 审稿时间：约2个月 SCI(2016)：6.403 SCI(2015)：6.399 复方中药制剂, objectType=tool_impact_factor, channel=null, level=null, likeNumber=328, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/16/5216d8362228f28bb1314281182c775b.jpg, createdBy=b64f1989189, createdName=京墨, createdTime=Thu Sep 06 00:00:00 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090445, encodeId=b88120904454a, content=请问accept多久后会受到proof邮件？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fa2c2358137, createdName=122c6795m57(暂无昵称), createdTime=Mon Sep 26 14:49:46 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229469, encodeId=40a61229469da, content=想问问这个杂志会要western blot的全膜吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a5e8120865, createdName=ms5000001165594838, createdTime=Wed Jun 29 14:54:14 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096008, encodeId=346c109600846, content=讨论一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096007, encodeId=cde3109600e27, content=引言和讨论之间有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548573, encodeId=275f5485e33e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：复方中药制剂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=373, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7581398151, createdName=ngx7912156, createdTime=Wed Oct 25 14:48:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547815, encodeId=241754e8152c, content=不知道怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=423, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/YConHRH5GCtcFEWO7xCkB10VsePH8PlzvattQoVRIQ7KJg26g6PvbkD8nE6Gsic5Nub2HzA4TsvkTQqEYUoz7pw/132, createdBy=288f2160779, createdName=liyu5975, createdTime=Sat Sep 30 14:40:00 CST 2017, time=2017-09-30, status=1, ipAttribution=)]

2017-09-30 liyu5975

不知道怎么样

423 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务